Brief: Aytu Biopharma QTRLY Net Revenue Of $27.7 Million Driven By 34% Growth In Rx Segment
14/11/2022 23:00
Nov 14 (Reuters) - Aytu Biopharma Inc AYTU.O :
* AYTU BIOPHARMA INC- QTRLY NET REVENUE OF $27.7 MILLION
DRIVEN BY
34% GROWTH IN RX SEGMENT
* AYTU BIOPHARMA INC- QTRLY LOSS PER SHARE $0.06
Further company coverage: AYTU.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aytu Biopharma
See all newsAytu Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary
Aytu BioPharma Q4 revenue beats analyst estimates on EXXUA sales
Aytu Biopharma Inc expected to post a loss of 32 cents a share - Earnings Preview
Aytu BioPharma Q3 revenue falls amid EXXUA launch
Aytu BioPharma Q2 revenue beats expectations